Overview:
On September 27, 1996, the Food and Drug Administration (FDA) approved a Haemophilus B conjugate vaccine. With medical science and technological advancements, vaccines have played an essential role in preventing the spread of infectious diseases. One such vaccine that has significantly contributed to the reduction of Haemophilus influenzae type B (Hib)-related illnesses is the Haemophilus B conjugate vaccine. Haemophilus b conjugate vaccine is a tetanus toxoid conjugate and is considered an active immunizing agent that helps prevent infection caused by the bacteria known as Haemophilus influenzae type B. The vaccine makes the body produce antibodies against the disease.
Haemophilus B conjugate vaccine is prepared by combining diphtheria, meningococcal, or tetanus-related substances. However, this vaccine cannot replace the regular vaccines for diphtheria, tetanus, or meningococcus in children and adults. All Haemophilus B conjugate vaccines act similarly but can be given at different ages or times. The vaccine was introduced in the 1980s and has since undergone various improvements. The introduction of this vaccine marked a significant milestone in pediatric healthcare, leading to a substantial decline in Hib-related diseases.
For Patients:
What Is Haemophilus Influenzae Type B?
Haemophilus influenzae type B is a bacterium mainly affecting infants and young children. It can lead to serious health complications, such as meningitis (infection affecting the meninges of the brain), pneumonia, epiglottitis (a throat infection that leads to suffocation), and sepsis. Before the introduction of the Haemophilus B conjugate vaccine, these infections were a leading cause of bacterial meningitis in children under five years old. Haemophilus influenzae type B meningitis can lead to death or leave the child with severe damage like deafness, mental retardation, epilepsy, or partial blindness.
What Is Haemophilus B Conjugate Vaccine?
The Haemophilus B conjugate vaccine was developed to provide immunity against Hib infections. Conjugate vaccines are unique in their approach, as they combine a protein from the surface of the bacteria with a carrier protein to stimulate a stronger immune response. Bacterial capsular polysaccharides have a common immunological property of T-independent B-cell activation but have varying chemical structures. It is associated with poor immunogenicity (the ability of cells to trigger an immune response) in infants and a failure to induce immunological memory at any age. Therefore, purified capsular polysaccharide vaccines are usually unsatisfactory in early childhood as the disease burden is the highest at this stage.
Protein polysaccharide conjugation solves the problems of polysaccharide immunogenicity in children by employing T cells to the immune response. Protein–polysaccharide conjugate vaccines for Haemophilus influenzae type B were the first to be introduced into common use within a population and have proved to be greatly effective in reducing the burden of Hib disease.
Haemophilus influenzae Type B conjugate vaccine is advised for all children two months to five years of age. This vaccine will be administered only by or under the doctor's supervision.
This product is also available in the following dosage forms:
-
Powder for solution.
-
Powder for suspension.
-
Solution.
Various bacteria responsible for invasive bacterial disease in children have a polysaccharide capsule. The capsule helps in the survival of these organisms during transmission and colonization; however, it also helps in their survival in the blood in the pathogenesis of invasive disease through resistance to complement-mediated killing and phagocytosis.
Antibody against the polysaccharide capsule is used for naturally acquired immunity against many organisms. The polysaccharide capsule of the following organisms provides an opportunity as well as a challenge for vaccine prevention of severe bacterial infections in children:
-
Salmonella typhi causes typhoid fever.
-
Haemophilus influenzae type B causes pneumonia.
-
Neisseria meningitidis causes meningococcal septicemia (severe blood infection).
-
Streptococcus pneumoniae causes pneumonia.
Initially, the Hib conjugate vaccine was a success due to its protective efficacy. However, the increase in Hib vaccine failures seen from 1999 onwards has highlighted the immune response, the complexity of the interaction between vaccines, and Hib population dynamics.
How Does Haemophilus Influenzae Type B Spread?
Hib generally spreads by sneezing and coughing like cold and flu. Hib bacteria can survive in the nose and throat of healthy individuals without causing any problems. However, healthy individuals can still pass it on and transfer the infection to others. Certain populations are at a higher risk of getting seriously ill from a Hib infection, including:
-
Infants and young children.
-
Elderly people.
-
Individuals with a weakened immune system, including those with spleen removed.
How Does the Haemophilus B Conjugate Vaccine Works?
The Haemophilus B conjugate vaccine stimulates the immune system to produce antibodies against the Hib bacterium. The conjugation process involves attaching the outer coating of the Hib bacteria to a carrier protein, making it further recognizable to the immune system. This allows the body to mount a robust defense against the bacteria after exposure, preventing infection or decreasing the severity of the illness.
What Is the Vaccination Schedule?
The Haemophilus B Conjugate vaccine is typically administered to infants in several doses. The recommended schedule may vary by region, but it often includes doses at two, four, and six months of age, with a booster shot given around 12 to 15 months. This schedule ensures that infants develop a strong and lasting immunity against Hib.
What Are the Side Effects?
Like any vaccine, the Haemophilus B conjugate vaccine might lead to mild side effects like:
-
Redness or swelling at the injection site.
-
Low-grade fever.
-
Irritability.
Serious side effects are rarely seen. As with any medical intervention, parents need to consult with healthcare providers to manage any concerns and ensure that the benefits of vaccination outweigh the potential risks.
For Doctors
Indications:
The Haemophilus B conjugate vaccine, or the Hib vaccine, is administered in infants and young children to protect against infections caused by Haemophilus influenzae type b (Hib). The vaccine is a critical component of routine childhood immunization programs and is indicated for the following populations:
The primary indication for the Hib vaccine is for infants and young children, particularly vulnerable to Hib infections. The vaccine is usually administered in a series of doses, with the first dose often given at two months of age, followed by additional doses at four and six months. A booster dose may be given around twelve to fifteen months.
-
Prevention of Meningitis: Haemophilus influenzae type B is a major cause of bacterial meningitis in children. The Hib vaccine is highly effective in preventing Hib-related meningitis, which can lead to severe neurological complications and even death.
-
Protection Against Pneumonia: Hib infections can lead to pneumonia, a respiratory infection that can be especially dangerous in infants and children. The Hib vaccine helps protect against Hib-induced pneumonia.
-
Prevention of Epiglottitis: Epiglottitis is a serious condition where the epiglottis, a flap-like structure in the throat, becomes inflamed and can lead to airway obstruction. Hib is one of the bacteria that can cause epiglottitis, and the vaccine helps prevent this potentially life-threatening condition.
-
Reduction of Other Invasive Diseases: Besides meningitis, pneumonia, and epiglottitis, Hib can cause other invasive diseases, such as sepsis and cellulitis. The Hib vaccine is designed to reduce the incidence of these serious and sometimes fatal conditions.
-
Community Protection (Herd Immunity): The Hib vaccine provides individual protection and contributes to community immunity. When an essential portion of the population is vaccinated, the bacterial spread is limited, protecting those at higher risk, such as individuals with weakened immune systems or those who cannot receive the vaccine for medical issues.
-
Global Immunization Efforts: The Hib vaccine is a crucial component of global immunization efforts to reduce the burden of vaccine-preventable diseases. It is often included in routine childhood vaccination schedules recommended by health authorities worldwide.
Administration:
A nurse or any other trained healthcare professional can administer this vaccine medically. It is administered into a muscle in the form of a shot. The exact schedule for the child's vaccines might differ based on the brand of medicine used and the child's age at the time of the first dose. Generally, a child will receive the first dose between two to six months of age, followed by two more doses with a time of eight weeks. The child is also given a booster dose at 15 to 18 months. However, this can be given until the age of five years. Ensuring that a child receives all vaccine doses in this series at scheduled appointments is essential. If the child does miss a dose of this vaccine, get another appointment as soon as possible. The child can receive other vaccines at the same time but in a different region of the body.
Pharmacokinetics:
Absorption: The Hib vaccine is administered through an intramuscular injection. The vaccine contains a conjugate of Haemophilus influenzae type B (Hib) polysaccharide with a carrier protein. Upon injection, the conjugate is absorbed at the injection site.
Distribution: Instead of traditional distribution within the bloodstream or tissues, the components of the Hib vaccine are recognized by the immune system cells, particularly antigen-presenting cells like dendritic cells and macrophages. These cells are crucial in presenting the vaccine components to other immune cells.
Activation of Immune Response: The primary action of the Hib vaccine is to stimulate the immune system. The conjugate structure ensures that the immune system recognizes the Hib polysaccharide as a foreign invader. This recognition triggers the antibody production and the activation of specific immune cells, such as B and T cells.
Metabolism and Excretion: Unlike traditional drugs that undergo metabolism and excretion, the components of the Hib vaccine are processed by the immune system. Once the immune response is activated, memory B and T cells are generated, providing long-lasting immunity. There is no conventional metabolic breakdown or excretion of vaccine components.
Drug Interactions: Although certain medicines must not be used together at all, in certain cases, two different medicines have to be administered together, even if an interaction is anticipated. In such cases, the doctor might alter the dose or take other precautions that may be required. When an individual receives this vaccine, the healthcare professional must be informed about any of the medicines listed below. Administration of this vaccine with any of the following medicines is usually not recommended but may sometimes be required.
-
Elivaldogene autotemcel.
-
Teplizumab-mzwv.
-
Ublituximab-xiiy.
Other Medical Problems:
Other medical problems might also affect the use of this vaccine. Inform the doctor about any other medical conditions, particularly the following:
-
Guillain-Barré Syndrome: It is characterized by severe nerve and muscle problems. If an individual with this syndrome has a history of administration of a vaccine with tetanus toxoid, the doctor will decide if the Haemophilus B conjugate vaccine can be given.
-
Weakened Immune System: This may not work as well in patients with this condition.
Specific Considerations:
While selecting a vaccine, the risks of taking the vaccine must be evaluated against the benefits. The doctor takes this decision with informed consent. For this vaccine, the following precautions must be considered:
-
Allergies: Inform the doctor if allergic to this medicine or other medicines. Also, inform healthcare professionals about different types of allergies, including dyes, foods, preservatives, or animals.
-
Pediatric: Major studies have not yet demonstrated pediatric-specific problems that would limit the use of this vaccine in children two months to five years of age. However, safety and efficacy are yet to be established in children six years of age and older and younger than two months.
-
Geriatric: The Haemophilus B conjugate vaccine (tetanus toxoid conjugate) is not recommended in adult or geriatric patients.
-
Breastfeeding: Studies suggest this vaccine poses minimal risk to the infant during breastfeeding. As part of routine childhood immunization programs, this vaccine has demonstrated its effectiveness in preventing severe illnesses caused by Haemophilus influenzae Type B. Ongoing research and public health initiatives will continue to refine vaccination strategies, ensuring the continued success of the Haemophilus B conjugate vaccine in safeguarding the health of infants and young children.
